SMTI — Sanara Medtech Income Statement
0.000.00%
Last trade - 00:00
- $260.05m
- $266.64m
- $64.99m
- 65
- 28
- 57
- 48
2019 December 31st | 2020 December 31st | 2021 December 31st | C2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 11.8 | 15.6 | 24.1 | 45.8 | 65 |
Cost of Revenue | |||||
Gross Profit | 10.6 | 14 | 21.8 | 39.5 | 57.1 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 14.5 | 20 | 31.5 | 58.4 | 69.2 |
Operating Profit | -2.74 | -4.45 | -7.38 | -12.5 | -4.22 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.84 | -4.45 | -7.99 | -13.9 | -4.44 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2.84 | -4.45 | -7.99 | -8.09 | -4.44 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -2.81 | -4.36 | -7.92 | -7.94 | -4.3 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.81 | -4.36 | -7.92 | -7.94 | -4.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.32 | -0.862 | -1.08 | -1 | -0.52 |